ASH 2015 – Multiple Myeloma

Daratumumab in combination with pomalidomide and dexamethasone is being evaluated in a 4-arm, multicenter, phase 1b study in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma. Initial findings show deep and durable responses, a high response rate, and good tolerability. Read More ›

R. Donald Harvey believes that developing well-tolerated drugs is the key to improving the standard of care in managing patients with hematologic malignancies. Read More ›

R. Donald Harvey stresses the importance of patient support services in addressing financial challenges and building support communities for both patients and their families. Read More ›

Ali McBride provides an overview of the role of the pharmacist and the importance of working with a broad team of healthcare providers in managing patients on oral oncolytics. Read More ›

R. Donald Harvey speaks about the addition of new medicines and how they can be included in the existing treatment armamentarium. Read More ›

Ali McBride discusses medicines that have been on the market for the last few years. Read More ›

Ali McBride speaks to the challenges of medication adherence, especially in the various settings. Read More ›

R. Donald Harvey discusseses his role in managing patients on this medication class. Read More ›

Ali McBride talks about patient issues with medication adherence and what payers are doing to ensure compliance. Read More ›